Zargis Cardioscan 'The Intelligent Stethoscope' Now Available on Amazon.com
STAMFORD, Conn., Dec. 14 Zargis Medical Corp., a majority-owned subsidiary of Speedus Corp. (Nasdaq: SPDE) and a spin-off from Siemens Corporate Research (NYSE: SI) announced today that it has begun selling its award-winning Zargis Cardioscan(TM) system on Amazon.com, America's largest online retailer.
Cardioscan and its accompanying Bluetooth®-enabled electronic stethoscope were jointly named Popular Science magazine's "2009 Innovation of the Year." Cardioscan is the world's first FDA-cleared medical device to identify and classify suspected systolic and diastolic heart murmurs and was described as "The Intelligent Stethoscope" by The Wall Street Journal when it was recognized with a Wall Street Journal Technology Innovation Award.
Cardioscan, along with the accompanying stethoscope, are currently for sale on Amazon.com at a special holiday price with free shipping. Orders placed by December 21st can be delivered by Christmas day.
Zargis selected Amazon.com because of Amazon's commitment to delivering the best possible shopping experience and the online retailer's "A-to-Z guarantee program", which provides Amazon.com customers with an added level of confidence when making purchases.
About Zargis Medical Corp.
Zargis Medical Corp. develops advanced diagnostic decision support products and services for primary care physicians, pediatricians, cardiologists and other healthcare professionals. Zargis was formed in 2001 when Siemens Corporate Research, a division of Siemens AG (NYSE: SI), and Speedus Corp. (Nasdaq: SPDE) co-invested to develop and market an advanced acoustic technology designed to detect heart abnormalities identified through analysis of heart sounds.
For additional information about Zargis or Speedus Corp., contact Peter Hodge at 888.773.3669 (ext. 23) or email@example.com, or visit the following Web sites: www.zargis.com and www.speedus.com.
Statements contained herein that are not historical facts, including but not limited to statements about the Company's product, corporate identity and focus, may be forward-looking statements that are subject to a variety of risks and uncertainties. There are a number of important factors that could cause actual results to differ materially from those expressed in any forward-looking statements made by the Company, including, but not limited to, the continuing development of the Company's sales, marketing and support efforts.
SOURCE Zargis Medical Corp.
You May Also Like